This was the stock's third consecutive day of losses.

Shares of Akero Therapeutics, Inc. (AKRO) jumped 3% on Friday afternoon after Jefferies said the company has a “promising” ...

Full results from the first phase 3 trial of UCB and Biogen's anti-CD40L antibody dapirolizumab pegol (DZP) in systemic lupus ...

In a report released today, Laura Chico from Wedbush maintained a Hold rating on Biogen (BIIB – Research Report), with a price target of $121.00. The company’s shares closed y ...

A company with profits isn’t always a great investment. Some struggle to maintain growth, face looming threats, or fail to ...

TD Cowen analyst Phil Nadeau maintained a Buy rating on Biogen (BIIB – Research Report) today and set a price target of $175.00. The company’s shares closed today at $133.06.

Since McKinney Health burst onto the scene in 2022, it has been carving out its place at the intersection of health and life.

UCB and Biogen's lupus candidate showed strong Phase 3 results, including fatigue improvement and higher remission versus ...

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $190.82, a high estimate of ...